Skip to content

Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis

A Multicenter, Randomized, Controlled Trial Comparing Cefepime Monotherapy Versus Combination of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-associated Peritonitis

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02872038
Enrollment
154
Registered
2016-08-18
Start date
2015-08-31
Completion date
2016-11-30
Last updated
2017-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal Dialysis Associated Peritonitis

Brief summary

The purpose of this study is to compare the efficacy of empirical antibiotics of CAPD-associated peritonitis with intraperitoneal, continuous dosing of cefepime monotherapy versus combination of cefazolin and ceftazidime. Patients were randomized to be administered either intraperitoneal cefepime 1 g loading then 250 mg all exchanges (treatment group) or cefazolin and ceftazidime (control group) in the same dose.

Detailed description

The International Society of Peritoneal Dialysis (ISPD) guideline suggest to use combination of antibiotics to cover both of gram positive and gram negative bacteria. The usual regimen in Thailand is cefazolin plus ceftazidime. Despite combination therapy, monotherapy is also possible for empirical treatment of CAPD-associated peritonitis since it helps to lowering staff burden and lowering risk of contamination. Cefepime could be an ideal antibiotic for empirical treatment of CAPD-associated peritonitis as it is an extended-spectrum cephalosporin, forth generation, covering most of gram positive and gram negative bacteria. In addition, cefepime is not broken down by many of the beta-lactamases and less beta-lactamases inducer. This study aims to prove the noninferiority of cefepime monotherapy to cefazolin plus ceftazidime for empirical treatment of CAPD-associated peritonitis. CAPD-associated peritonitis was diagnosed by at least two of the following criteria: abdominal pain or cloudy peritoneal dialysis fluid (PDF); PDF white cell count \> 100/μL with \> 50% polymorphonuclear(PMN); and positive gram stain or culture. The patients were randomized into two groups by block of four randomization, sealed envelope. Treatment group was treated with intraperitoneal (IP) cefepime 1 g loading following by maintenance dose 250 mg IP all exchanges. Control group was treated with cefazolin 1 g IP loading and ceftazidime 1 g IP loading following by maintenance dose of cefazolin and ceftazidime 250 mg IP all exchanges. If a patient had residual urine ≥ 100 ml/day, dose of antibiotics would be increased by 25%. On the first day, the initial blood tests for complete blood count, electrolyte, BUN, creatinine, calcium, phosphate and magnesium were obtained. While peritoneal dialysis fluid were collected using two methods of bacterial culture, both of centrifugation of 50 ml peritoneal dialysis fluid at 3,000 g for 15 minutes and bedside 5-10 ml of peritoneal dialysis fluid inoculated into the blood culture bottles. PDF gram stain and bacterial culture were done. The patients were followed on day 3, 5, 10, 14, 21 and 28 days after the completion of antibiotic course. If clinical improved, the antibiotics would be adjusted according to the culture result and sensitivity after day 5. If clinical not improved the antibiotics would be step up and Tenckhoff catheter removal was considered (on any day of treatment). The patients were treated at least 14 days or 21 days depend on the culture result (as the recommendation of ISPD guideline 2010).

Interventions

DRUGCefepime

Cefepime intraperitoneal continuous dosing

DRUGCefazolin plus Ceftazidime

Sponsors

The Kidney Foundation of Thailand
CollaboratorUNKNOWN
Siam Pharmaceutical Co Ltd
CollaboratorUNKNOWN
Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age more than 18 years * CAPD initiation more than 4 weeks

Exclusion criteria

* Exit site or tunnel infection * Sepsis * Previous CAPD-associated peritonitis treatment within 4 weeks * Drug allergy to cephalosporin * Tenckhoff catheter malfunction * Hospitalization more than 48 hours * Fungal or Mycobacterium infection * Suspected secondary peritonitis * Concomitant antibiotics.

Design outcomes

Primary

MeasureTime frameDescription
Primary response rateday 10 of treatmentResolution of clinical peritonitis and peritoneal dialysis fluid WBC \< 100 /μL with PMN \< 50% at day 10

Secondary

MeasureTime frameDescription
Initial response rateday 5 of treatmentResolution of clinical peritonitis and peritoneal dialysis fluid WBC \< 100 /μL with PMN \< 50% at day 5

Other

MeasureTime frameDescription
Complete cure rate28 days after completion of antibioticsComplete resolution without relapse or recurrent within 28 days after completion of antibiotics.
Relapse peritonitis rate28 days after completion antibioticsRecur of peritonitis with the same organism or sterile culture within 28 days after completion antibiotics
Recurrent peritonitis rate28 days after completion antibioticsRecur of peritonitis with different organism within 28 days after completion antibiotics
Death rate28 days after completion antibioticsDeath from any cause

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026